Skip to content

Research on the Application of Exhaled Volatile Organic Compounds (VOCs) in the Diagnosis, Subtyping, and Disease Control Assessment of Chronic Airway Diseases

Research on the Application of Exhaled Volatile Organic Compounds (VOCs) in the Diagnosis, Subtyping, and Disease Control Assessment of Chronic Airway Diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106120
Enrollment
Unknown
Registered
2025-07-17
Start date
2025-06-09
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Airway Diseases

Interventions

Gold Standard:The clinical reference standards (gold standards or reference criteria) used in this study for the diagnosis of chronic airway diseases (such as asthma, chronic obstructive pulmonary dis
Induced sputum eosinophil ratio >=2.5%
Fractional exhaled nitric oxide (FeNO) >=20 ppb
Allergen-driven (atopic).Non-Type 2 Asthma: Failing to meet an

Sponsors

The First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years and <=80 years, regardless of gender; 2.Healthy individuals and those diagnosed with chronic airway diseases (such as asthma, chronic obstructive pulmonary disease, etc.) in our department who meet relevant diagnostic criteria; 3.Disease in stable phase or clinical remission; 4.Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1.Chronic airway diseases in acute exacerbation phase within the past 4 weeks; 2.Pregnant individuals; 3.Malignant tumors, endocrine-related metabolic diseases (such as diabetes mellitus, hyperthyroidism, etc.), systemic infectious diseases (such as sepsis, severe pneumonia, etc.), and digestive system diseases (such as severe liver cirrhosis, ulcerative colitis, etc.); 4.History of pulmonary surgery or tuberculosis; 5.Severe hepatic/renal insufficiency: (1) Severe liver dysfunction: total bilirubin > 34.2 µmol/L, albumin reduction ( 4 seconds; decompensated liver cirrhosis, acute liver failure, etc., with complications such as ascites and hepatic encephalopathy; (2)Significant renal dysfunction: chronic kidney disease stages 4-5, glomerular filtration rate (GFR) < 30 ml/min/1.73m^2 with severe edema, uremic symptoms, etc.; heart failure (New York Heart Association class III-IV and left ventricular ejection fraction (LVEF) < 40%, etc.).

Design outcomes

Primary

MeasureTime frame
Volatile Organic Compounds(VOCs);

Secondary

MeasureTime frame
FEV1\FVC;VCmax;FVC;

Countries

China

Contacts

Public ContactShuoyao Qu

The First Affiliated Hospital of Air Force Medical University

1515073201@qq.com+86 135 7285 7122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026